Serum potassium monitoring and risk management measures during Finerenone medication

Finerenone is a new type of selective mineralocorticoid receptor antagonist, mainly used to treat patients with chronic kidney disease combined with type 2 diabetes. Although this type of drug has significant efficacy in delaying the deterioration of renal function and reducing adverse cardiovascular events, it also has a certain impact on regulating electrolytes, and in particular may cause an increase in blood potassium. Therefore, patients need to regularly monitor blood potassium levels during medication to prevent the occurrence of hyperkalemia.

Before initiating fenelidone, it is recommended that the patient's serum potassium level be assessed. If serum potassium is ≥5.0 mmol/L, it is usually not recommended to start treatment immediately, and measures should be taken to control serum potassium first. Doctors will also decide whether fenelidone is suitable for use based on the patient's renal function (such as eGFR value) and whether other drugs that affect potassium levels are used at the same time (such as ACE inhibitors, ARBs, potassium-sparing diuretics, etc.), and develop a personalized medication and monitoring plan.

The first few weeks after taking the drug are a critical period to monitor changes in serum potassium. Clinical practice generally recommends testing serum potassium at least once within 1 to 4 weeks after taking the drug, and then rechecking every 1 to 3 months. If the serum potassium level rises above 5.5 mmol/L during treatment, the medication should be suspended and the high potassium problem should be addressed. Only after the serum potassium drops back to a safe range (such as less than 5.0 mmol/L) can you re-evaluate whether to continue taking the medication to prevent severe hyperkalemia.
In addition, for the elderly, patients with advanced diabetic nephropathy, or people with existing cardiac insufficiency, more caution should be taken during medication. Patients should limit the intake of high-potassium foods, such as bananas, orange juice, nuts, etc., and promptly report suspected high-potassium symptoms such as palpitations, fatigue, nausea, etc. Doctors may also consider combining potassium-lowering drugs based on the patient's specific conditions. Through scientific monitoring and management, most patients can safely use fenelidone and give full play to its clinical value in the treatment of chronic kidney disease.
Reference: https://www.kerendia.com/